Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: A Pan-European analysis
2012 (English)In: Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, E-ISSN 1468-3083, Vol. 26, no 11, 1407-1414 p.Article in journal (Refereed) Published
Background Scalp psoriasis is a difficult to treat and usually chronic manifestation of psoriasis. The CalePso study showed that CPS (Clobex ® Shampoo) in maintenance therapy of scalp psoriasis (twice weekly) significantly increases the probability of keeping patient under remission during 6 months, compared with vehicle (40.3% relapses vs. 11.6% relapses, ITT). Objective The objective of the study was to assess the cost-effectiveness of a maintenance therapy with CPS vs. its vehicle in nine European countries. Methods A 24-week decision tree model was developed with 4-weekly time steps. The considered population has moderate scalp psoriasis successfully treated with a daily application of CPS up to 4 weeks. Data were taken from the CalePso study and from national experts' recommendations for alternative treatment choices, with their probabilities of success taken from literature to develop country-specific models. Health benefits are measured in disease-free days (DFD). The economic analysis includes drug and physician costs. A probabilistic sensitivity analysis (PrSA) assesses the uncertainty of the model. Results Depending on the country, the mean total number of DFDs per patient is 21-42% higher with CPS compared with vehicle, and the mean total cost is 11-31% lower. The mean costs per DFD are 30-46% lower with CPS compared with the vehicle. The PrSA showed in 1000 simulations that CPS is more effective vs. vehicle in 100% of the cases and less expensive than its vehicle in 80-99% of the cases. Conclusion This model suggests that CPS is cost-effective in maintaining the success achieved in moderate scalp psoriasis patients.
Place, publisher, year, edition, pages
2012. Vol. 26, no 11, 1407-1414 p.
bemethson, betamethasone, betamethasone dipropionate, betamethasone dipropionate plus calcipotriol, betamethasone valerate, calcipotriol, clarelux, clobetasol propionate, elucon, mometasone furoate, psodermil, shampoo, unclassified drug, xamiol, article, cost effectiveness analysis, drug cost, Europe, maintenance therapy, medical fee, priority journal, psoriasis, relapse, remission
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-184944DOI: 10.1111/j.1468-3083.2011.04305.xISI: 000310271000012OAI: oai:DiVA.org:uu-184944DiVA: diva2:570403